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Abstract
Background: Individuals of African ethnicity are disproportionately burdened with chronic kidney disease (CKD).
However, despite the genetic link, genetic association studies of CKD in African populations are lacking.
Methods: We conducted a systematic review to critically evaluate the existing studies on CKD genetic risk inferred
by polymorphism(s) amongst African populations in Africa. The study followed the HuGE handbook and PRISMA
protocol. We included studies reporting on the association of polymorphism(s) with prevalent CKD, end-stage
renaldisease (ESRD) or CKD-associated traits. Given the very few studies investigating the effects of the same
single nucleotide polymorphisms (SNPs) on CKD risk, a narrative synthesis of the evidence was conducted.
Results: A total of 30 polymorphisms in 11 genes were investigated for their association with CKD, ESRD or
related traits, all using the candidate-gene approach. Of all the included genes, MYH9, AT1R and MTHFR genes
failed to predict CKD or related traits, while variants in the APOL1, apoE, eNOS, XPD, XRCC1, renalase, ADIPOQ, and CCR2
genes were associated with CKD or other related traits. Two SNPs (rs73885319, rs60910145) and haplotypes (G-A-G; G1;
G2) of the apolipoprotein L1 (APOL1) gene were studied in more than one population group, with similar
association with prevalent CKD observed. The remaining polymorphisms were investigated in single studies.
Conclusion: According to this systematic review, there is currently insufficient evidence of the specific polymorphisms
that poses African populations at an increased risk of CKD. Large-scale genetic studies are warranted to better
understand susceptibility polymorphisms, specific to African populations.
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Background
Chronic kidney disease (CKD) is fast becoming a leading
public health issue in Africa, with an estimated preva-
lence of 14.3% in the general population, and 36.1% in
high-risk populations [1]. Due in part to increasing rates
of type 2 diabetes, hypertension and obesity, the preva-
lence of CKD continues to rise [2]. However, marked
variability in the incidence of CKD between population
groups, suggests additional factors contributing to CKD
aetiology [3]. Indeed, prevalent end-stage renal disease
(ESRD), which is the terminal stage of CKD, is 4-fold
higher among African ethnicity as compared to Euro-
pean ethnicity [4, 5] and individuals of African ethnicity
progress faster from moderately decreased kidney func-
tion to ESRD [6]; thus highlighting African ethnicity as a
contributing risk factor for CKD [4, 5].
Over the past decade, through the use of genome-
wide association studies (GWAS), researchers have
identified various genomic regions with common gen-
etic variants associated with CKD traits [7]. However, a
limitation of the majority of GWAS’s conducted to date
is the paucity of studies conducted in individuals of
African ancestry and even less in Africans living in Af-
rica [7–10]. Despite, Africa being one of the most eth-
nically and genetically diverse regions of the world [11],
these populations are understudied, with most of the
common loci associated with CKD in non-African pop-
ulations not being replicated in African populations.
Though African migrants living in Europe and America
are genetically linked with African ancestry [12, 13], these
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genetic variants cannot be extrapolated to Africans resid-
ing in Africa. This is mainly due to genetic admixture of
American and European populations, as well as differ-
ences in environment, cultural and lifestyles [11]. Accord-
ingly, identification of genetic loci for CKD in African
populations will help to advance our understanding of the
underpinnings of CKD in individuals of African descent.
There is currently no systematic review evaluating
the CKD-associated genes found in African populations
residing in Africa. The main purpose of this review is
thus to critically evaluate the existing studies on CKD
genetic risk inferred by polymorphisms amongst Afri-
can populations in Africa, and explore the specific ef-




The review was conducted using the Preferred Report-
ing Items for Systematic Reviews and Meta-Analysis
PRISMA framework [14] and HuGENET™ HuGE Re-
view handbook [15]. The methods of the analysis and
inclusion criteria were specified in advance and
documented in a protocol in the PROSPERO database
(registration number: CRD42017058440).
Selection of eligible studies, types of studies and sources
of information
Relevant studies published until August 2017 were
identified through a comprehensive electronic search
of major databases such as MEDLINE (via PubMed),
EBSCOhost, Scopus, and Web of Science, using an Af-
rican search filter [16] and without any starting date
or language restrictions. Medical Subject Headings
(MeSH) terms and Boolean operators, such as AND/
OR/NOT, were used to string terms together (refer to
Additional files 1, 2, 3 and 4: Tables S1–S4). Publica-
tion bibliographies were searched to further enhance
the search strategy.
Data collection
Two authors (CG and YYY) independently conducted the
database searches and sequentially (titles, abstracts and
then full texts) screened them for inclusion (Fig. 1). In sit-
uations of disagreements between the two authors, a third
author (APK) arbitrated for eligibility. The inclusion
criteria was that a study had to be an original study
Fig. 1 Selection process for studies included in the systematic review
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containing independent data that were obtained from
case-control or cohort studies, which specifically con-
ducted genetic association analyses on African popula-
tions residing in Africa. These studies had to report on
study population characteristics, methods, CKD or
renal traits (such as serum creatinine, estimated glomerular
filtration rate (eGFR), urinary albumin excretion), genes
and polymorphisms, genotyping technique(s), statistical
analyses, and report on allele and genotype frequencies.
Studies were excluded if, [1] the conducted analyses were
exclusively on migrant African populations, [2] the en-
tire cohort consisted of only high-risk individuals (a
population of only type 2 diabetic or hypertensive pa-
tients), [3] the study did not report the estimate effects
and/or p-values, allele and genotype frequencies, and if
[4] the study was a meta-analysis, review or any other
form of publication that do not have primary data. Full
articles were obtained for all abstracts and titles that
met inclusion criteria as well as those that certainty of
inclusion was unclear. The two authors (CG and YYY)
screened the full-text articles, and selected full manu-
scripts according to the inclusion criteria. Disagree-
ments were resolved through discussion or if consensus
were not met, reviewed by a third author (APK). The
reasons for excluding studies were also recorded.
Data extraction, assessment and synthesis
The data extracted from selected articles included the
name of the first author and year of publication, study
setting and design, population characteristics, genetic
models used for measures of association, adjustment (if
any) for confounding variables, allele and genotype fre-
quencies, and the study outcome. Data extraction was
done by one author (CG), and another author (YYY)
verified the accuracy and validity of extracted data. As
recommended by Sagoo et al. [17], we assessed the exist-
ence of bias considering the following: case definition,
population stratification, reporting of methods used
(sample size of a study population, genotyping method
and its reliability/accuracy, validation of results, statis-
tical analyses). Given the very few studies investigating
the effects of the same SNPs on CKD risk across differ-
ent settings/countries, attempting to pool studies were
deemed meaningless, thus, we opted to conduct a narra-
tive synthesis of the evidence instead of a meta-analysis.
Results
Study selection
We retrieved 2787 citations (962 from EBSCOhost; 754
from MEDLINE; 568 from SCOPUS; 501 from Web of Sci-
ence; 2 from publication bibliography) from our searches.
Of these, 2771 citations were not eligible for inclusion for
the following reasons: duplicate (n = 1567) or irrelevant to
this review based on the title or abstract (n = 1204). Conse-
quently, 16 full-text articles were reviewed and of those,
three citations were excluded, based on not meeting the in-
clusion criteria of this review, resulting in 13 eligible articles
retained for the systematic review (Fig. 1).
Characteristics of included studies
Table 1 describes the characteristics of the genetic stud-
ies included in this review. All the studies were con-
ducted between 2009 and 2016 with the vast majority
conducted in Egypt (n = 7), followed by Nigeria and
South Africa (n = 2, each), and Morocco and Tunisia
each with only one reported study on CKD genetic as-
sociation. Overall, nine studies (69.2%) were from three
north-African countries [18–26] and the rest from
sub-Saharan African countries [27–30]. The study
population ranged from 87 to 859 participants per
study, with the mean age ranging from 8.7 to 58.9 years
and a male predominance in all except the two South
African studies, where only 22–23% were male [27, 28].
Of the thirteen studies included, kidney dysfunction
was characterized mainly by an estimated glomerular
filtration rate (eGFR) equal to or less than 60 ml/min/
1.73m2 [18, 23, 25, 27, 28]. The remaining studies used
other surrogate measures to determine kidney dysfunc-
tion, which included ESRD (undergoing haemodialysis)
[19, 21, 22, 24, 26], elevated serum creatinine levels
[20] and a combination of serum creatinine levels
greater or equal to 170 μmol/l and dipstick proteinuria
greater or equal to 2 [30] or serum creatinine above
1.4 mg/dl (men) and 1.2 mg/dl (women) and urinary al-
bumin to creatinine ratio (ACR) above 30 mg/g [29].
The CKD patients included in these studies were of dif-
ferent aetiologies, reflective of the diversity in nephrop-
athy present in Africa.
Table 2 summarizes the polymorphisms investigated in
the included studies. Thirty different polymorphisms
(including SNP, indels and repeats) in 11 genes have been
studied in various population groups in Africa. Of the
polymorphisms investigated by selected studies, only three
SNPs of the APOL1 gene (rs73885319, rs60910145,
rs71785313) were studied in more than one population
group, which included the Yoruba [29] and Igbo [30]
tribes of Nigeria and the South African mixed-race popu-
lation group [27]. The remaining 27 polymorphisms of the
MYH9, apoE, AT1R, eNOS, MTHFR, XPD, XRCC1, rena-
lase, ADIPOQ and CCR2 genes were each studied in only
one ethnic group. Eight of the included genetic association
studies assessed the distribution of allele frequency by for-
mally testing for Hardy-Weinberg equilibrium (HWE),
and one study assumed HWE without formal testing [21].
Of those formally tested, only one polymorphism showed
a departure from HWE (MYH9 rs4821480), and was
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subsequently removed from further association analysis in
that study [28]. Adjustment for confounders was not
consistent across studies, with six studies not providing
information on the degree of adjustment or variables
accounted for [21–26]. The remaining seven studies all
adjusted for at least age and gender [18–20, 27–30]. In all
studies, the genomic DNA was extracted from whole
blood samples and genotyped by methods including Taq-
Man genotyping assays, polymerase chain reaction restric-
tion fragment length polymorphism (PCR-RFLP) and
gel-electrophoresis and confirmed by PCR-sequencing.
Association of genetic markers with CKD and related traits
According to the studies included in this review, some
SNP’s investigated in the MYH9 [28], AT1R [19], and
MTHFR [20] genes failed to predict prevalent CKD, ESRD
or related traits (serum creatinine, eGFR and ACR), while
variants in the APOL1 [27, 29, 30], apoE [21], eNOS [18,
20], XPD [22], XRCC1 [22], renalase [23, 26], ADIPOQ
[31] and CCR2 [24] genes were associated with either
prevalent CKD or progression of CKD, ESRD, or other
surrogate measures of renal function.
The majority of CKD-associated polymorphisms were
conducted in single studies. In a Moroccan population, the
e4 allele and the E3E4 genotype of the apoE gene demon-
strated a significant association with ESRD (OR= 0.491; p
= 0.009 and OR= 0.316, p < 0.001, e4 and E3E4, respect-
ively) [21]. However, this association was unadjusted for
any potential confounder effects. Both Kerkeni et al. [20]
and Elshamaa et al. [18] conducted genetic association
studies on SNPs in the eNOS gene, adjusting for potential
confounders, albeit different population groups and dif-
ferent SNPs. According to Kerkeni et al. [20], the eNOS
SNP found in exon 7 (G894 T) was an independent risk
factor of severity of CKD (p = 0.01) in Tunisian adults.
Similarly, Elshamaa et al. [18] found the a-allele in the
eNOS (intron 4) gene to predict ESRD in Egyptian chil-
dren (p < 0.05) [18]. Radwan et al. [22] investigated
three polymorphisms in the DNA repair genes (XPD
and XRCC1) and found that patients with XRCC1–399
Arg/Gln genotype had a significantly higher risk of de-
veloping ESRD (OR: 2.48; 95% CI: 1.36–4.52). Further-
more, the haplotypes containing XRCC1–399 Arg/Gln
and XPD-312 Asp/Asn as well as XRCC1–399 Arg/Gln
and XPD-751 Lys/Gln were significantly associated with
the development of ESRD (OR: 8.35, 95%CI: 1.94–
35.85, p = 0.004 and OR: 9.22, 95%CI: 2.14–39.71, p =
0.003, respectively). Two studies, both in Egyptian pop-
ulations, investigated polymorphisms of the renalase
gene [23, 26]. Rezk et al. [23] found that patients with
the CC genotype and carriers of C allele of the
rs2296545 renalase gene were significantly more likely
to have prevalent CKD (CC genotype; OR: 4.84, 95%CI:
1.28–18.2, p = 0.02 and C-carrier; OR: 2.14, 95%CI:
1.07–4.26, p = 0.04). Abdallah et al. [26], conversely
found that carriers of the G allele of the rs2576178 and
rs10887800 renalase gene were associated with increased
risk of developing ESRD (OR: 7.188, 95%CI: 3.5–14.7, p <
0.05 and OR: 12.3, 95%CI: 5.6–27.1; p < 0.05). However, in
both studies no adjustments were made for potential con-
founders. ADIPOQ+276G > T was also investigated for as-
sociation with ESRD in Egyptian children [31]. This study
suggested that the +276G > T allele may indirectly contrib-
ute to CKD susceptibility by increasing adiponectin levels
(p = 0.04). Elhelbawy et al. [24] found a significant associ-
ation between CCR2–641 and chronic renal failure, par-
ticularly the AG genotype (OR = 2.8, 95% CI = 1.40–5.51),
combined AG and GG genotypes (OR = 4.1, 95% CI =
1.27–13.03) and A allele (OR = 2.9, 95% CI = 1.14–7.3).
As seen in Table 2, only polymorphisms in the APOL1
gene were investigated in more than one ethnic group,
with the observed association similar in at least two popu-
lation groups. Indeed, according to the study conducted in
the Yoruba tribe of Nigeria [29], two single APOL1 SNPs
(rs73885319 and rs60910145) were significantly associated
with CKD under all genetic models, with the largest effect
under the recessive model (OR: 3.85 and 3.12 for
rs73885319, and rs60910145, respectively). Furthermore,
due to the linkage disequilibrium (D-prime = 1.00, r2 =
0.82) between the two SNPs, adjusting for either SNP re-
sulted in no association for the other SNP. Similarly, albeit
a different population (mixed-race South Africans), Mat-
sha et al. [27] found the same two single SNPs
(rs73885319 and rs60910145) to be associated with preva-
lent CKD, however only under the recessive model (p =
0.047) (as measured by the CKD-EPI eGFR equation),
even after adjusting for multiple confounders. The study
did not observe an association between these single
APOL1 SNPs and any of the other surrogate measures of
kidney function. Tayo et al. [29] also investigated the ad-
justed association of APOL1 haplotypes, namely the
G-A-G haplotype (rs9622363–rs73885319–rs60910145)
and the G1 haplotype (rs73885319 and rs60910145) and
found both to be significantly associated with CKD under
all models of genetic association (G-A-G, ORs: 2.26; p =
0.005, OR: 2.54; p = 0.023 and OR: 3.79; p = 0.041 for the
additive, dominant and recessive modes; G1, OR: 2.25; p
= 0.006, OR: 2.52; p = 0.025 and OR: 3.80; p = 0.041 for the
additive, dominant and recessive modes). Ulasi et al. [30]
also conducted a study on the APOL1 G1 haplotype
(rs73885319 and rs60910145) and G2 (rs71785313)
(Wt:G1 or Wt:G2; G1:G1 or G1:G2 or G2:G2) in the Igbo
tribe of Nigeria. This study found no significant effect of
the Wt:G1 or Wt:G2 one-copy, but observed a high asso-
ciation between APOL1 two-risk alleles (G1:G1 or G1:G2
or G2:G2) and CKD (OR: 4.8; p = 5.1E-03), even after
adjusting for various confounders.
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Discussion
To the best of our knowledge, this is the first compre-
hensive report of the current evidence on genetic poly-
morphisms associated with renal disease amongst
populations in Africa. This review highlights the lack of
genetic association studies conducted within the borders
of Africa, despite the known genetic link to CKD and
the genetic diversity in Africa.
All the studies included in this review used the can-
didate gene approach, and amongst these, only MYH9
polymorphisms has been previously investigated by
GWAS and showed directional association with CKD
in populations elsewhere [10]. Indeed, multiple MYH9
SNPs have been identified as powerful predictors of
non-diabetic kidney disease in African Americans [32],
Hispanic-Americans [33], and individuals of European
ancestry [34]. However, from this review we found no
evidence for the associative role of MYH9 polymor-
phisms in non-diabetic CKD patients in Africa, as all
eight SNPs investigated in populations from Nigeria
and South Africa failed to predict prevalent CKD or
any other surrogate measure of kidney function [28,
29]. Differences in linkage disequilibrium structure
might however explain the lack of genetic association
in studies conducted in these African populations. In-
deed, previous studies have shown that the G1 and G2
risk variants of the APOL1 gene are in strong linkage
disequilibrium with variants in MYH9. Indeed, most of
the association previously attributed to MYH9 variants
or haplotypes with CKD could be explained by their
genetic linkage with APOL1 polymorphisms in popula-
tions of African ancestry residing outside the African
continent [35, 36]. In contrast, the studies included in
this review instead observed independent association
between four SNPs of the APOL1 gene and with either
prevalent CKD, serum creatinine, eGFR or ACR in the
included studies [27, 29, 30]. This strong association
between APOL1 polymorphisms and non-diabetic kid-
ney disease found in studies in this review have been
replicated in several studies [37–45] since the initial
findings reported in African Americans [35, 36]. In
addition, as reported in all the above mentioned stud-
ies, the risk is mostly conferred by the presence of two
copies of the risk alleles, that is, homozygous or com-
pound heterozygous compared to no or one APOL1
risk variant [35, 36]. It would therefore be of great
interest if larger population studies are conducted to
ascertain the kidney disease-APOL1 association across
African population groups.
Currently, the role of the polymorphisms in the apoE
[21], eNOS [18, 20], XPD [22], XRCC1 [22], renalase [23,
26], ADIPOQ [31] and CCR2 [24] genes in the aetiology of
CKD remains controversial and further larger studies
should be conducted to confirm these results in population
groups within Africa. Certainly, various polymorphisms
have been associated, both directly and indirectly, with in-
creased CKD risk in certain populations and decreased
CKD risk in others or alternatively have no convincing as-
sociation. This is true for the polymorphisms investigated
in the current review. For example, Lahrach et al. [21]
showed that the e4 allele and the E3E4 genotype of the
apoE gene demonstrated a strong association with ESRD,
similar to a study conducted in a Swedish population [46].
However, a study conducted in African Americans and
European Americans showed an opposite effect, with the
e4 allele being associated with decreased risk of ESRD pro-
gression and decreased risk of prevalent ESRD [47], with
no association found between the e4 allele and CKD in
Asian populations [48]. The genetic link between eNOS (4a;
intron4) and ESRD [18] and CKD severity (G894 T; exon7)
[20] have also been studied in two African populations, and
in both studies, as in various other studies [49–51], the
polymorphisms under investigation were found to be sig-
nificantly associated with kidney disease. However, this as-
sociation between polymorphisms of eNOS and kidney
disease is not fully elucidated, as the direction and magni-
tude have been found to differ by population and even
within the same population. For example, Bellini et al. [52]
demonstrated a strong association between eNOS 4a poly-
morphism and ESRD risk in a Brazilian population, while
Marson et al. [53] found no significant correlation between
eNOS 4a polymorphism and ESRD risk in a similar Brazil-
ian population group. The association between DNA repair
genes (XPD and XRCC1) and kidney disease is not
commonly investigated, and with the exception of the study
reviewed in this publication [22], has only been investi-
gated previously in a Turkish population [54]. Both
studies showed an association between DNA repair
gene polymorphisms and ESRD development. However,
the effect estimates amongst the African population
were higher than that reported in the Turkish popula-
tion. From the included studies, it is evident that inves-
tigating regional differences in the relationship between
genes and CKD risk within Africa has relevance, con-
sidering the genetic diversity among ethnic population
groups in the continent [55].
Our study has some limitations, which include the
small number of existing studies, which precluded stat-
istical analysis by means of meta-analysis. Furthermore,
as a result of existing genetic association studies not al-
ways reporting on key methodological information that
includes testing the HWE, the sample size/power calcu-
lations, clear description of controls, consideration and
correction for population stratification, as well as the
levels of adjustment, it is difficult to draw definitive in-
ferences from these studies. In addition, the sample size
of the included studies was much smaller than other
studies conducted outside of Africa, thus as a result it
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is possible that with larger sample sizes, additional pre-
viously proposed candidate genes may have reached
statistical significance. Indeed, with the largest included
study comprising 859 participants [27], it is highly likely
that most existing studies on the genetics of kidney dis-
ease in Africa have been underpowered to replicate exist-
ing loci or estimate effects with precision. Furthermore,
the majority of included studies were conducted in Egyp-
tian populations, thus not covering all the scope of genetic
variations that exist on the African continent. The age
range, which varied from approximately 9–60 years, and
the range of covariates included in adjustment of the esti-
mates of association also differed substantially across stud-
ies and could possibly affect between-studies comparisons.
In addition, since we had no access to individual partici-
pant data, refined analyses and accounting for potential
confounders and other types of bias, could not be exe-
cuted. However, despite the shortcomings of this review,
the strength resides in the fact that, according to our
knowledge, this is the first study to systematically and
comprehensively review the existing data on genetic asso-
ciation studies of CKD in the context of Africa.
Conclusion
The putative genetic risk factors that have emerged
from current data represent the most promising kid-
ney disease susceptibility genes described to date in
populations within Africa. However, larger-scale gen-
etic association studies are needed to further expand
our knowledge of the underlying genetic mechanisms
of kidney disease among populations within Africa.
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